{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:38:58Z","timestamp":1793392738476,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s10072-021-05182-6","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T23:02:19Z","timestamp":1616194939000},"page":"5037-5043","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Nabiximols and botulinum toxin injections for patients with multiple sclerosis: efficacy on spasticity and spasms in a single-centre experience"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4518-518X","authenticated-orcid":false,"given":"Arianna","family":"Sartori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3249-4792","authenticated-orcid":false,"given":"Alessandro","family":"Dinoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Stragapede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Mazzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elisa","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Pasquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Bratina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5305-6268","authenticated-orcid":false,"given":"Paolo","family":"Manganotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"5182_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/1352458509359721","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA (2018) Multiple Sclerosis. N Engl J Med 378:169\u2013180. https:\/\/doi.org\/10.1177\/1352458509359721","journal-title":"N Engl J Med"},{"key":"5182_CR2","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1007\/s00415-018-8759-1","volume":"265","author":"D Dressler","year":"2018","unstructured":"Dressler D, Bhidayasiri R, Bohlega S, Chana P, Chien HF, Chung TM, Colosimo C, Ebke M, Fedoroff K, Frank B, Kaji R, Kanovsky P, Ko\u00e7er S, Micheli F, Orlova O, Paus S, Pirtosek Z, Relja M, Rosales RL, Sag\u00e1stegui-Rodr\u00edguez JA, Schoenle PW, Shahidi GA, Timerbaeva S, Walter U, Saberi FA (2018) Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy. J Neurol 265:856\u2013862. https:\/\/doi.org\/10.1007\/s00415-018-8759-1","journal-title":"J Neurol"},{"key":"5182_CR3","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3109\/00207454.2012.762364","volume":"123","author":"C Oreja-Guevara","year":"2013","unstructured":"Oreja-Guevara C, Gonz\u00e1lez-Segura D, Vila C (2013) Spasticity in multiple sclerosis: results of a patient survey. Int J Neurosci 123:400\u2013408. https:\/\/doi.org\/10.3109\/00207454.2012.762364","journal-title":"Int J Neurosci"},{"key":"5182_CR4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/ane.12202","volume":"129","author":"P Flachenecker","year":"2014","unstructured":"Flachenecker P, Henze T, Zettl UK (2014) Spasticity in patients with multiple sclerosis - clinical characteristics, treatment and quality of life. Acta Neurol Scand 129:154\u2013162. https:\/\/doi.org\/10.1111\/ane.12202","journal-title":"Acta Neurol Scand"},{"key":"5182_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/ane.12139","volume":"129","author":"J Svensson","year":"2014","unstructured":"Svensson J, Borg S, Nilsson P (2014) Costs and quality of life in multiple sclerosis patients with spasticity. Acta Neurol Scand 129:13\u201320. https:\/\/doi.org\/10.1111\/ane.12139","journal-title":"Acta Neurol Scand"},{"key":"5182_CR6","doi-asserted-by":"publisher","first-page":"850","DOI":"10.3109\/00207454.2013.812084","volume":"123","author":"R Arroyo","year":"2013","unstructured":"Arroyo R, Massana M, Vila C (2013) Correlation between spasticity and quality of life in patients with multiple sclerosis: The CANDLE study. Int J Neurosci 123:850\u2013858. https:\/\/doi.org\/10.3109\/00207454.2013.812084","journal-title":"Int J Neurosci"},{"key":"5182_CR7","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1177\/1352458516643600","volume":"22","author":"S Otero-Romero","year":"2016","unstructured":"Otero-Romero S, Sastre-Garriga J, Comi G, Hartung HP, Soelberg S\u00f8rensen P, Thompson AJ, Vermersch P, Gold R, Montalban X (2016) Pharmacological management of spasticity in multiple sclerosis: systematic review and consensus paper. Mult Scler 22:1386\u20131396. https:\/\/doi.org\/10.1177\/1352458516643600","journal-title":"Mult Scler"},{"key":"5182_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1586\/14737175.2013.865880","volume":"13","author":"R Gold","year":"2013","unstructured":"Gold R, Oreja-Guevara C (2013) Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines. Expert Rev Neurother 13:55\u201359. https:\/\/doi.org\/10.1586\/14737175.2013.865880","journal-title":"Expert Rev Neurother"},{"key":"5182_CR9","doi-asserted-by":"publisher","unstructured":"Shakespeare D, Boggild M, Young CA (2003) Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.cd001332","DOI":"10.1002\/14651858.cd001332"},{"key":"5182_CR10","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1468-1331.2010.03328.x","volume":"18","author":"A Novotna","year":"2011","unstructured":"Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, Gasperini C, Pozzilli C, Cefaro L, Comi G, Rossi P, Ambler Z, Stelmasiak Z, Erdmann A, Montalban X, Klimek A, Davies P (2011) A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex\u00ae), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 18:1122\u20131131. https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03328.x","journal-title":"Eur J Neurol"},{"key":"5182_CR11","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1177\/1352458510395056","volume":"17","author":"A Erwin","year":"2011","unstructured":"Erwin A, Gudesblatt M, Bethoux F, Bennett SE, Koelbel S, Plunkett R, Sadiq S, Stevenson VL, Thomas AM, Tornatore C, Zaffaroni M, Hughes M (2011) Intrathecal baclofen in multiple sclerosis: too little, too late? Mult Scler J 17:623\u2013629. https:\/\/doi.org\/10.1177\/1352458510395056","journal-title":"Mult Scler J"},{"key":"5182_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.msard.2018.10.009","volume":"27","author":"Y Sammaraiee","year":"2019","unstructured":"Sammaraiee Y, Yardley M, Keenan L, Buchanan K, Stevenson V, Farrell R (2019) Intrathecal baclofen for multiple sclerosis related spasticity: A twenty year experience. Mult Scler Relat Disord 27:95\u2013100. https:\/\/doi.org\/10.1016\/j.msard.2018.10.009","journal-title":"Mult Scler Relat Disord"},{"key":"5182_CR13","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.410280407","volume":"28","author":"BJ Snow","year":"1990","unstructured":"Snow BJ, Tsui JKC, Bhatt MH, Varelas M, Hashimoto SA, Calne DB (1990) Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 28:512\u2013515. https:\/\/doi.org\/10.1002\/ana.410280407","journal-title":"Ann Neurol"},{"key":"5182_CR14","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1136\/jnnp.68.6.707","volume":"68","author":"N Hyman","year":"2000","unstructured":"Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B, Poewe W, Wissel J, Bain P, Glickman S, Sayer A, Richardson A, Dott C (2000) Botulinum toxin (Dysport\u00ae) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 68:707\u2013712. https:\/\/doi.org\/10.1136\/jnnp.68.6.707","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5182_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s00415-016-8304-z","volume":"264","author":"D Dressler","year":"2017","unstructured":"Dressler D, Bhidayasiri R, Bohlega S, Chahidi A, Chung TM, Ebke M, Jacinto LJ, Kaji R, Ko\u00e7er S, Kanovsky P, Micheli F, Orlova O, Paus S, Pirtosek Z, Relja M, Rosales RL, Sag\u00e1stegui-Rodr\u00edguez JA, Schoenle PW, Shahidi GA, Timerbaeva S, Walter U, Saberi FA (2017) Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. J Neurol 264:112\u2013120. https:\/\/doi.org\/10.1007\/s00415-016-8304-z","journal-title":"J Neurol"},{"key":"5182_CR16","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1177\/0269215517745348","volume":"32","author":"X Fu","year":"2018","unstructured":"Fu X, Wang Y, Wang C, Wu H, Li J, Li M, Ma Q, Yang W (2018) A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis. Clin Rehabil 32:713\u2013721. https:\/\/doi.org\/10.1177\/0269215517745348","journal-title":"Clin Rehabil"},{"key":"5182_CR17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1159\/000441619","volume":"74","author":"M Trojano","year":"2015","unstructured":"Trojano M, Vila C (2015) Effectiveness and tolerability of THC\/CBD oromucosal spray for multiple sclerosis spasticity in Italy: first data from a large observational study. Eur Neurol 74:178\u2013185. https:\/\/doi.org\/10.1159\/000441619","journal-title":"Eur Neurol"},{"key":"5182_CR18","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/jcph.670","volume":"845\u2013851","author":"D Paolicelli","year":"2016","unstructured":"Paolicelli D, Direnzo V, Manni A, D\u2019Onghia M, Tortorella C, Zoccolella S, Di Lecce V, Iaffaldano A, Trojano M (2016) Long-term data of efficacy, safety, and tolerability in a real-life setting of THC\/CBD oromucosal spray-treated multiple sclerosis patients. J Clin Pharmacol 845\u2013851:845\u2013851. https:\/\/doi.org\/10.1002\/jcph.670","journal-title":"J Clin Pharmacol"},{"key":"5182_CR19","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1136\/jnnp-2015-312591","volume":"87","author":"F Patti","year":"2016","unstructured":"Patti F, Messina S, Solaro C, Amato MP, Bergamaschi R, Bonavita S, Bruno Bossio R, Brescia Morra V, Costantino GF, Cavalla P, Centonze D, Comi G, Cottone S, Danni M, Francia A, Gajofatto A, Gasperini C, Ghezzi A, Iudice A, Lus G, Maniscalco GT, Marrosu MG, Matta M, Mirabella M, Montanari E, Pozzilli C, Rovaris M, Sessa E, Spitaleri D, Trojano M, Valentino P, Zappia M (2016) Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J Neurol Neurosurg Psychiatry 87:944\u2013951. https:\/\/doi.org\/10.1136\/jnnp-2015-312591","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"5182_CR20","doi-asserted-by":"publisher","first-page":"e0180651","DOI":"10.1371\/journal.pone.0180651","volume":"12","author":"S Messina","year":"2017","unstructured":"Messina S, Solaro C, Righini I, Bergamaschi R, Bonavita S, Bossio RB, Brescia Morra V, Costantino G, Cavalla P, Centonze D, Comi G, Cottone S, Danni MC, Francia A, Gajofatto A, Gasperini C, Zaffaroni M, Petrucci L, Signoriello E, Maniscalco GT, Spinicci G, Matta M, Mirabella M, Ped\u00e0 G, Castelli L, Rovaris M, Sessa E, Spitaleri D, Paolicelli D, Granata A, Zappia M, Patti F, SA.FE. study group (2017) Sativex in resistant multiple sclerosis spasticity: discontinuation study in a large population of Italian patients (SA.FE. study). PLoS One 12(8):e0180651. https:\/\/doi.org\/10.1371\/journal.pone.0180651","journal-title":"PLoS One"},{"key":"5182_CR21","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1136\/jnnp-2019-322480","volume":"91","author":"CG Chisari","year":"2020","unstructured":"Chisari CG, Solaro C, Annunziata P, Bergamaschi R, Bianco A, Bonavita S, Brescia Morra V, Bruno Bossio R, Capello E, Castelli L, Cavalla P, Costantino G, Centonze D, Cottone S, Danni MC, Esposito F, Gajofatto A, Gasperini C, Guareschi A, Lanzillo R, Lus G, Maniscalco GT, Matta M, Paolicelli D, Petrucci L, Pontecorvo S, Righini I, Rovaris M, Sessa E, Spinicci G, Spitaleri D, Valentino P, Zaffaroni M, Zappia M, Patti F (2020) Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study. J Neurol Neurosurg Psychiatry 91:914\u2013920. https:\/\/doi.org\/10.1136\/jnnp-2019-322480","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5182_CR22","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s10072-017-3078-3","volume":"38","author":"P Latino","year":"2017","unstructured":"Latino P, Castelli L, Prosperini L, Marchetti MR, Pozzilli C, Giovannelli M (2017) Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study. Neurol Sci 38:1841\u20131848. https:\/\/doi.org\/10.1007\/s10072-017-3078-3","journal-title":"Neurol Sci"},{"issue":"7","key":"5182_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0219670","volume":"14","author":"AE Grimaldi","year":"2019","unstructured":"Grimaldi AE, De Giglio L, Haggiag S, Bianco A, Cortese A, Crisafulli SG, Monteleone F, Marfia G, Prosperini L, Galgani S, Mirabella M, Centonze D, Pozzilli C, Castelli L (2019) The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray). PLoS One 14(7):e0219670. https:\/\/doi.org\/10.1371\/journal.pone.0219670","journal-title":"PLoS One"},{"key":"5182_CR24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000357427","volume":"71","author":"P Flachenecker","year":"2014","unstructured":"Flachenecker P, Henze T, Zettl UK (2014) Nabiximols (THC\/CBD Oromucosal Spray, Sativex\u00ae) in clinical practice - results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol 71:271\u2013279. https:\/\/doi.org\/10.1159\/000357427","journal-title":"Eur Neurol"},{"key":"5182_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10072-015-2392-x","volume":"37","author":"L Ferr\u00e8","year":"2016","unstructured":"Ferr\u00e8 L, Nuara A, Pavan G, Radaelli M, Moiola L, Rodegher M, Colombo B, Keller Sarmiento IJ, Martinelli V, Leocani L, Martinelli Boneschi F, Comi G, Esposito F (2016) Efficacy and safety of nabiximols (Sativex\u00ae) on multiple sclerosis spasticity in a real-life Italian monocentric study. Neurol Sci 37:235\u2013242. https:\/\/doi.org\/10.1007\/s10072-015-2392-x","journal-title":"Neurol Sci"},{"key":"5182_CR26","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1212\/WNL.45.4.712","volume":"45","author":"MA Grazko","year":"1995","unstructured":"Grazko MA, Polo KB, Jabbari B (1995) Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 45:712\u2013717. https:\/\/doi.org\/10.1212\/WNL.45.4.712","journal-title":"Neurology"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05182-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-021-05182-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05182-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T21:06:56Z","timestamp":1638565616000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-021-05182-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5182"],"URL":"https:\/\/doi.org\/10.1007\/s10072-021-05182-6","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]},"assertion":[{"value":"21 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol and procedures employed in this study were approved by the Local Ethical Committee. An informed consent was signed by all participants prior to assessment, according to the Declaration of Helsinski (October 2013 version).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}